undamentalytics Newsletter
Sign in

Omniab, Inc. income statement

In fiscal 2025, Omniab, Inc. reported revenue of $18.7m, down 29.3% on the year before, operating income of −$69.0m (a -369.5% margin) and net income of −$64.8m, or −$0.57 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue355934261940
Research and development394857554843
General and administrative172533312927
Operating income−36−27−69−75−69−47
Interest expense00————
Income before tax−34−26−64−71−66−44
Income tax−7−4−14−9−2−0
Net income−27−22−51−62−65−43
Diluted EPS−$0.33−$0.26−$0.51−$0.61−$0.57−$0.34
Diluted shares (average)83m85m100m102m114m129m
EBITDA−19−8−50−51−47−37

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: OABI vs TKNOOABI vs RPIDMXCT vs OABIBNGO vs OABI

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Omniab, Inc.'s SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Omniab, Inc.